Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
Kalbe Farma Tbk
KLBF
Sector: Healthcare
Industry: Pharmaceuticals
Sub Sector: Pharmaceuticals & Health Care Research
Sub Industry: Pharmaceuticals
Live quote
tidak tersedia
Highlight Keuangan (2026 Q2) (In Rp)
EPS
82
ROE
15,78%
ROA
11,61%
Book Value
520
Net Income
1,92 T
Total Sales
19,48 T
Total Assets
33,08 T
DER
0.30x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
30,52%
PT LADANG IRA PANEN 🔗
10,47%
Corporate · Lokal
PT GIRA SOLE PRIMA 🔗
10,31%
Corporate · Lokal
PT SANTA SEHA SANADI 🔗
10,08%
Trustee Bank · Lokal
PT LUCASTA MURNING CEMERLANG 🔗
9,48%
Private Equity · Lokal
PT DIPTANALA BAHANA 🔗
9,30%
Corporate · Lokal
PT BINA ARTA CHARISMA 🔗
8,21%
Corporate · Lokal
PT GRIYA INSANI CAKRA SADAYA 🔗
3,43%
Firm · Lokal
PT KALBE FARMA TBK 🔗
3,34%
Corporate · Lokal
DJS KETENAGAKERJAAN PROGRAM JAMINAN HARI TUA 🔗
2,01%
Insurance · Lokal
HSBC-FUND SERVICES, THE OVERLOOK PARTNERS FUND L.P. 🔗
1,48%
Mutual Funds · Asing
GOVERNMENT OF NORWAY 🔗
1,37%
Sovereign Wealth Fund · Asing
Tentang Perusahaan
PT Kalbe Farma Tbk (the Company) was established in the Republic of Indonesia, within the framework of the Domestic Capital Investment Law No. 6 Year 1968, as amended by Law No. 12 Year 1970, basedon Notarial Deed No. 3 of Raden Imam Soesetyo Prawirokoesoemo datedon September 10th, 1966. The Company, which started commercial operation in 1966.
Produk & Lini Bisnis
The Company is primarily engaged in the development, manufacturing and trading of pharmaceutical preparation including medicines and consumer health products.
Dewan Direksi
BR
Bernadette Ruth Irawati Stiady
President Director
SD
Sie Djohan
Director
M
Mulialie
Director
JI
Jos Iwan Atmadjaja
Director
KS
Kartika Setiabudy
Director
Dewan Komisaris
V
Vidjongtius
President Commissioner
SO
Santoso Oen
Commissioner
RH
Ronny Handiana
Commissioner
FA
Ferdinand Aryanto
Commissioner
LH
Lilis Halim
Independent Commissioner
RK
Rhenald Kasali
In dependent Commissioner
Anak Usaha & Afiliasi
NamaDomisili%
 %
PT Bintang Toedjoe
Pharmaceutical
 Jakarta 100.00%
PT Hexpharm Jaya Laboratories
Pharmaceutical
 Jakarta 100.00%
PT Saka Farma Laboratories
Pharmaceutical
 Jakarta 100.00%
PT Finusolprima Farma Int.
Pharmaceutical
 Jakarta 100.00%
PT Bifarma Adiluhung
Health screening service
 Jakarta 100.00%
Innogene Kalbiotech Pte. Ltd.
Agent and representative for biotechnology products
 Singapore 93.34%
PT Dankos Farma
Pharmaceutical
 Jakarta 100.00%
PT Pharma Metric Labs.
Quality Control Certification Service and Clinical Trial for Pharmaceutical and Consumer Health Products
 Jakarta 81.64%
PT KalGen DNA
Screening Service, Supporting Diagnostic Test and Reagen Production
 Jakarta 60.00%
PT Kalbio Global Medika
Manufacturing of Biologic Products
 Jakarta 100.00%
PT Kalbe Genexine Biologics
Pharmaceutical
 Jakarta 60.00%
PT Innolab Sains Internasional
Health Screening Service
 Jakarta 60.00%
PT global Onkolab Farma
Pharmaceutical
 Jakarta 100.00%
PT Kalbe Myanmar Company Ltd.
Pharmaceutical
 Myanmar 100.00%
%
PT Sanghiang Perkasa
Health Foods
 Jakarta 100.00%
PT Kalbe Morinaga Indonesia
Health Foods
 Jakarta 70.00%
PT Hale International
Health Drinks
 Bogor 100.00%
PT Kalbe Milko Indonesia
Health Foods
 Bogor 51.00%
PT Global Vita Nutritech
Premix Industry
 Jakarta 100.00%
%
PT Enseval Putera Megatrading Tbk
Distribution of Pharmaceutical Products, Consumer Products, Medical Equipment, Cosmetics and Other Trading Products
 Jakarta 91.80%
PT Tri Sapta Jaya
Distribution of Pharmaceutical Products, Consumer Products, Medical Equipment, Cosmetics and Other Trading Products
 Jakarta 91.80%
PT Millenia Dharma Insani
Health Care Clinics
 Jakarta 91.80%
PT Enseval Medika Prima
Trading of Medical and Laboratory Equipment and Supplies
 Jakarta 91.80%
PT Global Chemindo Megatrading
Trading of Raw Materials for Pharmaceutical Products
 Jakarta 91.80%
PT Global Karsa Medika
Wholesale trading of pharmaceutical, medical equipment, foods and drinks
 Jakarta 91.80%
PT Renalmed Tiara Utama
Trading of Consumable Products for Hemodialysis Therapy
 Jakarta 90.65%
Kalbe Vision Pte. Ltd
Development, Production, Marketing and Distribution of Opthalmic Products
 Singapore 100.00%
Kalbe International Pte.Ltd.
Wholesale of Pharmaceutical, Consumer Health and Nutrition Products
 Singapore 100.00%
Asiawide Kalbe Philippines, Inc.
Marketing and Distribution of Energy Drinks in a Ready-to-Drink Format
 Philippines 50.00%
PT Karsa Lintas Buwana
Advertising
 Jakarta 100.00%
Kalbe Malaysia Sdn. Bhd.
Wholesale of Pharmaceutical and Medical Products
 Malaysia 100.00%
PT Medika Renal Citraprima
Hemodialysis Clinic, Trading of Consumable Products for Hemodialysis Therapy
 Jakarta 91.80%
PT Medika Komunika Teknologi
E-commerce, web portal and online media services
 Jakarta 50.00%
PT Cakra Radha Mustika
Digital marketing services
 Jakarta 100.00%
PT Karya Hasta Dinamika
Home delivery service
 Jakarta 100.00%
Kalbe Global Pte. Ltd
Holding company
 Singapore 100.00%
Trend Keuangan (5 periode terakhir) — hover bar untuk detail
Total Sales Net Income (+) Net Income (-)
35,3M 26,5M 17,7M 8,8M 0 Sales 2025Q2: Rp 17.079.294.370 Net Income 2025Q2: Rp 1.974.937.979 2025Q2 Sales 2025Q3: Rp 25.988.296.572 Net Income 2025Q3: Rp 2.631.345.329 2025Q3 Sales 2025Q4: Rp 35.324.544.000 Net Income 2025Q4: Rp 3.664.998.000 2025Q4 Sales 2026Q1: Rp 9.678.361.000 Net Income 2026Q1: Rp 1.028.927.000 2026Q1 Sales 2026Q2: Rp 19.478.807.000 Net Income 2026Q2: Rp 1.919.463.000 2026Q2
2025 Q2
EPS 84
ROE 17,64%
2025 Q3
EPS 75
ROE 15,27%
2025 Q4
EPS 78
ROE 15,72%
2026 Q1
EPS 88
ROE 16,94%
2026 Q2
EPS 82
ROE 15,78%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
PeriodeTotal SalesNet IncomeTotal AssetsTotal EquityEPSROEDER
2026 Q2 19,48 T 1,92 T 33,08 T 24,33 T 82 15,78% 0.30x
2026 Q1 9,68 T 1,03 T 31,99 T 24,30 T 88 16,94% 0.26x
2025 Q4 35,32 T 3,66 T 30,70 T 23,31 T 78 15,72% 0.26x
2025 Q3 25,99 T 2,63 T 30,10 T 22,98 T 75 15,27% 0.23x
2025 Q2 17,08 T 1,97 T 29,51 T 22,40 T 84 17,64% 0.24x
Trend Harga Penutupan & Book Value — hover titik untuk detail
Close Price Book Value
1,6K 1,3K 1,0K 727 425 Book Value 2025Q2: Rp 478 Close 2025Q2: Rp 1.525 2025Q2 Book Value 2025Q3: Rp 491 Close 2025Q3: Rp 1.130 2025Q3 Book Value 2025Q4: Rp 498 Close 2025Q4: Rp 1.205 2025Q4 Book Value 2026Q1: Rp 519 Close 2026Q1: Rp 970 2026Q1 Book Value 2026Q2: Rp 520 Close 2026Q2: Rp 765 2026Q2
2025 Q2
Close 1.525
BV 478
ROA 13,39%
2025 Q3
Close 1.130
BV 491
ROA 11,66%
2025 Q4
Close 1.205
BV 498
ROA 11,94%
2026 Q1
Close 970
BV 519
ROA 12,87%
2026 Q2
Close 765
BV 520
ROA 11,61%
History Harga Penutupan & Book Value
TahunQrtClose Price (Rp)Book Value (Rp)ROA
2026 2 765 520 11,61%
2026 1 970 519 12,87%
2025 4 1.205 498 11,94%
2025 3 1.130 491 11,66%
2025 2 1.525 478 13,39%
Data diperbarui pada: 2026-05-12 11:00:22